Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review

James F.H. Pittaway, Christopher Harrison, Yumie Rhee, Muriel Holder-Espinasse, Alan E. Fryer, Tim Cundy, William M. Drake, Melita D. Irving

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background: Hajdu-Cheney syndrome (HCS) (#OMIM 102500) is a rare, autosomal dominant condition that presents in early childhood. It is caused by mutations in the terminal exon of NOTCH2, which encodes the transmembrane NOTCH2 receptor. This pathway is involved in the coupled processes of bone formation and resorption. The skeletal features of HCS include acro-osteolysis of the digits and osteoporosis commonly affecting vertebrae and long bones. Fractures are a prominent feature and are associated with significant morbidity. There is no specific treatment, but with both acro-osteolysis and generalized osteoporosis, it is possible that anti-resorptive treatment might be of benefit. However, to date only a few case reports have evaluated the effectiveness of bisphosphonate treatment. Methods: We describe the clinical features, treatment regimens and response to bisphosphonate treatment in 7 newly described patients aged 6-39 with HCS, and pooled the data with that from 8 previously published cases (a total of 17 courses of treatment in 15 individuals). Results: The mean lumbar spine bone mineral density (BMD) z-score before treatment was - 2.9 (SD 1.2). In 14 courses of treatment (82%), there was an increase in BMD with bisphosphonate treatment, but the impact (in terms of change in spinal BMD z-score) appeared to be less with advancing age (p = 0.01). There was no evidence that acro-osteolysis was prevented. Conclusions: Although individual response is variable and age-related, the data support a role for bisphosphonates in preventing or treating spinal osteoporosis in HCS, but bone loss from the lumbar spine may be rapid after cessation.

Original languageEnglish
Article number47
JournalOrphanet Journal of Rare Diseases
Volume13
Issue number1
DOIs
Publication statusPublished - 2018 Apr 4

Fingerprint

Hajdu-Cheney Syndrome
Diphosphonates
Osteoporosis
Acro-Osteolysis
Bone Density
Spine
Therapeutics
Genetic Databases
Bone and Bones
Bone Resorption
Osteogenesis
Exons

All Science Journal Classification (ASJC) codes

  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Pittaway, James F.H. ; Harrison, Christopher ; Rhee, Yumie ; Holder-Espinasse, Muriel ; Fryer, Alan E. ; Cundy, Tim ; Drake, William M. ; Irving, Melita D. / Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review. In: Orphanet Journal of Rare Diseases. 2018 ; Vol. 13, No. 1.
@article{eba99c6a000c46478287f659c893bf38,
title = "Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review",
abstract = "Background: Hajdu-Cheney syndrome (HCS) (#OMIM 102500) is a rare, autosomal dominant condition that presents in early childhood. It is caused by mutations in the terminal exon of NOTCH2, which encodes the transmembrane NOTCH2 receptor. This pathway is involved in the coupled processes of bone formation and resorption. The skeletal features of HCS include acro-osteolysis of the digits and osteoporosis commonly affecting vertebrae and long bones. Fractures are a prominent feature and are associated with significant morbidity. There is no specific treatment, but with both acro-osteolysis and generalized osteoporosis, it is possible that anti-resorptive treatment might be of benefit. However, to date only a few case reports have evaluated the effectiveness of bisphosphonate treatment. Methods: We describe the clinical features, treatment regimens and response to bisphosphonate treatment in 7 newly described patients aged 6-39 with HCS, and pooled the data with that from 8 previously published cases (a total of 17 courses of treatment in 15 individuals). Results: The mean lumbar spine bone mineral density (BMD) z-score before treatment was - 2.9 (SD 1.2). In 14 courses of treatment (82{\%}), there was an increase in BMD with bisphosphonate treatment, but the impact (in terms of change in spinal BMD z-score) appeared to be less with advancing age (p = 0.01). There was no evidence that acro-osteolysis was prevented. Conclusions: Although individual response is variable and age-related, the data support a role for bisphosphonates in preventing or treating spinal osteoporosis in HCS, but bone loss from the lumbar spine may be rapid after cessation.",
author = "Pittaway, {James F.H.} and Christopher Harrison and Yumie Rhee and Muriel Holder-Espinasse and Fryer, {Alan E.} and Tim Cundy and Drake, {William M.} and Irving, {Melita D.}",
year = "2018",
month = "4",
day = "4",
doi = "10.1186/s13023-018-0795-5",
language = "English",
volume = "13",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",
number = "1",

}

Pittaway, JFH, Harrison, C, Rhee, Y, Holder-Espinasse, M, Fryer, AE, Cundy, T, Drake, WM & Irving, MD 2018, 'Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review', Orphanet Journal of Rare Diseases, vol. 13, no. 1, 47. https://doi.org/10.1186/s13023-018-0795-5

Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review. / Pittaway, James F.H.; Harrison, Christopher; Rhee, Yumie; Holder-Espinasse, Muriel; Fryer, Alan E.; Cundy, Tim; Drake, William M.; Irving, Melita D.

In: Orphanet Journal of Rare Diseases, Vol. 13, No. 1, 47, 04.04.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review

AU - Pittaway, James F.H.

AU - Harrison, Christopher

AU - Rhee, Yumie

AU - Holder-Espinasse, Muriel

AU - Fryer, Alan E.

AU - Cundy, Tim

AU - Drake, William M.

AU - Irving, Melita D.

PY - 2018/4/4

Y1 - 2018/4/4

N2 - Background: Hajdu-Cheney syndrome (HCS) (#OMIM 102500) is a rare, autosomal dominant condition that presents in early childhood. It is caused by mutations in the terminal exon of NOTCH2, which encodes the transmembrane NOTCH2 receptor. This pathway is involved in the coupled processes of bone formation and resorption. The skeletal features of HCS include acro-osteolysis of the digits and osteoporosis commonly affecting vertebrae and long bones. Fractures are a prominent feature and are associated with significant morbidity. There is no specific treatment, but with both acro-osteolysis and generalized osteoporosis, it is possible that anti-resorptive treatment might be of benefit. However, to date only a few case reports have evaluated the effectiveness of bisphosphonate treatment. Methods: We describe the clinical features, treatment regimens and response to bisphosphonate treatment in 7 newly described patients aged 6-39 with HCS, and pooled the data with that from 8 previously published cases (a total of 17 courses of treatment in 15 individuals). Results: The mean lumbar spine bone mineral density (BMD) z-score before treatment was - 2.9 (SD 1.2). In 14 courses of treatment (82%), there was an increase in BMD with bisphosphonate treatment, but the impact (in terms of change in spinal BMD z-score) appeared to be less with advancing age (p = 0.01). There was no evidence that acro-osteolysis was prevented. Conclusions: Although individual response is variable and age-related, the data support a role for bisphosphonates in preventing or treating spinal osteoporosis in HCS, but bone loss from the lumbar spine may be rapid after cessation.

AB - Background: Hajdu-Cheney syndrome (HCS) (#OMIM 102500) is a rare, autosomal dominant condition that presents in early childhood. It is caused by mutations in the terminal exon of NOTCH2, which encodes the transmembrane NOTCH2 receptor. This pathway is involved in the coupled processes of bone formation and resorption. The skeletal features of HCS include acro-osteolysis of the digits and osteoporosis commonly affecting vertebrae and long bones. Fractures are a prominent feature and are associated with significant morbidity. There is no specific treatment, but with both acro-osteolysis and generalized osteoporosis, it is possible that anti-resorptive treatment might be of benefit. However, to date only a few case reports have evaluated the effectiveness of bisphosphonate treatment. Methods: We describe the clinical features, treatment regimens and response to bisphosphonate treatment in 7 newly described patients aged 6-39 with HCS, and pooled the data with that from 8 previously published cases (a total of 17 courses of treatment in 15 individuals). Results: The mean lumbar spine bone mineral density (BMD) z-score before treatment was - 2.9 (SD 1.2). In 14 courses of treatment (82%), there was an increase in BMD with bisphosphonate treatment, but the impact (in terms of change in spinal BMD z-score) appeared to be less with advancing age (p = 0.01). There was no evidence that acro-osteolysis was prevented. Conclusions: Although individual response is variable and age-related, the data support a role for bisphosphonates in preventing or treating spinal osteoporosis in HCS, but bone loss from the lumbar spine may be rapid after cessation.

UR - http://www.scopus.com/inward/record.url?scp=85044976506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044976506&partnerID=8YFLogxK

U2 - 10.1186/s13023-018-0795-5

DO - 10.1186/s13023-018-0795-5

M3 - Review article

C2 - 29618366

AN - SCOPUS:85044976506

VL - 13

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 47

ER -